| Symbol
| GRIN2D
| contributors: mct - updated : 16-11-2016
|
| HGNC name
| glutamate receptor, ionotropic, N-methyl D-aspartate 2D
|
| HGNC id
| 4588
|
| corresponding disease(s)
|
EIEE46
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| constitutional
|
|
|
| loss of function
|
GRIN2B and GRIN2D-deficiency protected retinal ganglion cells (RGCs) from NMDA-induced excitotoxic retinal cell death  | |
Variant & Polymorphism
| 
| |
Candidate gene
| Marker
| its expression was shown be predictive of improved survival in CRC | Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| cancer | digestive | colon | |
| promising target for the future treatment of colorectal cancer | | neurology | neurodegenerative | Parkinson/dementia Parkinsonism | |
| may represent potential therapeutic targets for modulating subthalamic neuron activity in neurological disorders such as Parkinson disease | | neurology | neurodegenerative | alzheimer | |
| GRIN2D and DOCK3 might be potential therapeutic targets for treating neurodegenerative diseases such as Alzheimer disease | | neurosensorial | visual | | |
| GRIN2D and DOCK3 might be potential therapeutic targets for treating normal tension glaucoma |
| | |